GlassScriptPhysician profile
Paul Sharkey
NPI 1912989690
$18,818.58
in general payments reported to CMS, 2019-2025
46 companies · $4,077 in 2025
The $4,077 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $665 · 2021: $1,679 · 2022: $2,316 · 2023: $2,370 · 2024: $6,632 · 2025: $4,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,766 · Consulting Fee: $3,165 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,765.86 |
| Consulting Fee | $3,165.00 |
| Education | $148.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,488.18 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Pharmaceuticals, INC. | $3,283.64 | 2022-2024 | Dupixent |
| Glaxosmithkline, LLC. | $2,091.51 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,262.38 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,087.67 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $929.46 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Genentech USA, INC. | $571.93 | 2019-2025 | Xolair |
| Abbvie INC. | $559.01 | 2021-2025 | Ubrelvy, Qulipta, Rinvoq |
| Pfizer INC. | $524.76 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $524.20 | 2020-2024 | Austedo Xr, Ajovy, Austedo |
| Phathom Pharmaceuticals, INC. | $485.83 | 2024-2025 | Voquezna |
| Kaleo, INC. | $373.07 | 2020-2023 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.04 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $338.36 | 2019-2021 | |
| Pharming Healthcare, INC. | $313.04 | 2019-2025 | Ruconest |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $295.84 | 2024-2025 | Nemluvio |
| Csl Behring | $273.73 | 2021-2025 | Privigen, Hizentra, Andembry |
| Grifols USA, LLC | $244.26 | 2022-2025 | Xembify, Gamunex-C |
| Biocryst US Sales Co., LLC | $189.20 | 2021-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $181.31 | 2024-2025 | |
| Blueprint Medicines Corporation | $166.01 | 2023-2024 | Ayvakit |
| Amgen INC. | $122.83 | 2019-2025 | Tezspire |
| Optinose US, INC. | $121.23 | 2019-2023 | |
| Lilly USA, LLC | $121.14 | 2020-2025 | Ebglyss, Taltz |
| Jazz Pharmaceuticals INC. | $108.91 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $98.74 | 2023-2025 | Ryaltris |
| Leo Pharma INC. | $93.58 | 2024 | Adbry |
| Corium, LLC | $59.62 | 2023 | Azstarys |
| Lundbeck LLC | $50.24 | 2024-2025 | Vyepti, Rexulti |
| Incyte Corporation | $47.41 | 2022-2023 | Opzelura |
| Kowa Pharmaceuticals America, INC. | $47.07 | 2024-2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.07 | 2023-2025 | Xifaxan |
| Shire North American Group INC | $43.56 | 2019 | |
| Merck Sharp & Dohme LLC | $40.99 | 2021-2023 | Belsomra |
| Biocryst Pharmaceuticals, INC. | $38.59 | 2020 | |
| Hospira, INC. | $34.40 | 2024-2025 | |
| Axsome Therapeutics, INC. | $29.62 | 2022 | |
| Novo Nordisk INC | $27.28 | 2021 | |
| Alk-Abello, INC | $22.17 | 2023 | Grastek, Odactra, Ragwitek |
| Mylan Specialty L.P. | $20.31 | 2024 | Yupelri |
| Cycle Pharmaceuticals INC | $19.79 | 2025 | Sajazir |
| Supernus Pharmaceuticals, INC. | $18.07 | 2019 | |
| Depuy Synthes Sales INC. | $14.16 | 2022 | |
| Eisai INC. | $13.11 | 2020 | |
| Nevro Corp. | $11.94 | 2022 | |
| Upsher-Smith Laboratories LLC | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Sharkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.